Brand Name

Carteolol

View Brand Information
FDA approval date: January 05, 2000
Classification: beta-Adrenergic Blocker
Form: Solution

What is Carteolol?

Carteolol Hydrochloride Ophthalmic Solution 1% has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Preparation of a new fixed-combination carteolol-netarsudil ophthalmic solution via one-pot pH-adjusting solubilization strategy for glaucoma treatment.
Preparation of a new fixed-combination carteolol-netarsudil ophthalmic solution via one-pot pH-adjusting solubilization strategy for glaucoma treatment.
Journal: Drug delivery
Published: August 15, 2026
To Investigate the Effect of Combined Use of 0.01% Atropine and 2% Carteolol Hydrochloride Eye Drops on Early-Onset Myopic Control in Western Chinese Children.
To Investigate the Effect of Combined Use of 0.01% Atropine and 2% Carteolol Hydrochloride Eye Drops on Early-Onset Myopic Control in Western Chinese Children.
Journal: Ophthalmic epidemiology
Published: July 21, 2026
Thermoresponsive Hydroxybutyl Chitosan-Assisted Carteolol Delivery with Pulsed Dye Laser for Superficial Infantile Hemangiomas: An Exploratory Randomized Study.
Thermoresponsive Hydroxybutyl Chitosan-Assisted Carteolol Delivery with Pulsed Dye Laser for Superficial Infantile Hemangiomas: An Exploratory Randomized Study.
Journal: Clinical, cosmetic and investigational dermatology
Published: April 17, 2026
View All Latest Advances